Osteoporosis prevention

Current Opinion in Rheumatology

Volumn 23, Issue 2, 2011, Pages 203-210

  Grossman, Jennifer M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

osteoporosis; prevention; screening

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DENOSUMAB; ESTROGEN; GLUCOCORTICOID; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ALCOHOL CONSUMPTION; ARTICLE; CHILDHOOD; DIET; DRUG EFFICACY; ESTROGEN THERAPY; EXERCISE; FALLING; FRACTURE; HEREDITY; HIP FRACTURE; HUMAN; LIFESTYLE MODIFICATION; MASS SCREENING; MORBIDITY; MORTALITY; OSTEOPOROSIS; PREGNANCY; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; VITAMIN SUPPLEMENTATION;

ACCIDENTAL FALLS; EXERCISE; HUMANS; LIFE STYLE; MOTOR ACTIVITY; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RISK FACTORS;

EID: 79951576390     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283439426     Document Type: Article

References (85)

1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94:646-650.
2. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994; 4:368-381.
3. US Department of Health and Human Services. Bone health and osteoporosis: a report of the surgeon general. Rockville, Maryland, USA: US Department of Health and Human Services; 2004.
4. Hernandez CJ, Beaupre GS, Carter DR. A theoretical analysis of the relative influences of peak BMD, age-related bone loss and menopause on the development of osteoporosis. Osteoporos Int 2003; 14:843-847. (Pubitemid 37462135)
5. Rizzoli R, Bianchi ML, Garabedian M, etal. Maximizing bone mineral mass gain during growth for the prevention of fractures in the adolescents and the elderly. Bone 2010; 46:294-305.
6. Duncan EL, Brown MA. Clinical review 2: genetic determinants of bone density and fracture risk: state of the art and future directions. J Clin Endocrinol Metab 2010; 95:2576-2587.
7. Lorentzon M, Eriksson AL, Nilsson S, et al. Association between physical activity and BMD in young men is modulated by catechol-O-methyltransferase (COMT) genotype: the GOOD study. J Bone Miner Res 2007; 22:1165-1172. (Pubitemid 351339698)
8. Suuriniemi M, Suominen H, Mahonen A, et al. Estrogen receptor alpha polymorphism modifies the association between childhood exercise and bone mass: follow-up study. Pediatr Exerc Sci 2007; 19:444-458. (Pubitemid 350224176)
9. Baird J, Kurshid MA, Kim M, etal. Does birthweight predict bone mass in adulthood? A systematic review and meta-analysis. Osteoporos Int 2010. [Epub ahead of print]
10. Cooper C, Westlake S, Harvey N, et al. Review: developmental origins of osteoporotic fracture. Osteoporos Int 2006; 17:337-347.
11. Martin R, Harvey NC, Crozier SR, et al. Placental calcium transporter (PMCA3) gene expression predicts intrauterine bone mineral accrual. Bone 2007; 40:1203-1208. (Pubitemid 46550980)
12. Cooper C, Harvey N, Cole Z, et al. Developmental origins of osteoporosis: the role of maternal nutrition. Adv Exp Med Biol 2009; 646:31-39.
13. Javaid MK, Crozier SR, Harvey NC, et al. Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study. Lancet 2006; 367:36-43. (Pubitemid 43038668)
14. Greer FR, Krebs NF. Optimizing bone health and calcium intakes of infants, children, and adolescents. Pediatrics 2006; 117:578-585. (Pubitemid 46071626)
15. Bailey RL, Dodd KW, Goldman JA, etal. Estimation of total usual calcium and vitamin D intakes in the United States. J Nutr 2010; 140:817-822.
16. Huncharek M, Muscat J, Kupelnick B. Impact of dairy products and dietary calcium on bone-mineral content in children: results of a meta-analysis. Bone 2008; 43:312-321.
17. Janz KF, Letuchy EM, Eichenberger Gilmore JM, et al. Early physical activity provides sustained bone health benefits later in childhood. Med Sci Sports Exerc 2010; 42:1072-1078.
18. Baxter-Jones AD, Kontulainen SA, Faulkner RA, Bailey DA. A longitudinal study of the relationship of physical activity to bone mineral accrual from adolescence to young adulthood. Bone 2008; 43:1101-1107.
19. Nilsson M, Ohlsson C, Mellstrom D, Lorentzon M. Previous sport activity during childhood and adolescence is associated with increased cortical bone size in young adult men. J Bone Miner Res 2009; 24:1 25-133.
20. Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007; 370:657-666. (Pubitemid 47285316)
21. Reid IR, Bolland MJ, Grey A. Effect of calcium supplementation on hip fractures. Osteoporos Int 2008; 19:1119-1123.
22. Bischoff-Ferrari HA, Dawson-Hughes B, Baron JA, et al. Calcium intake and hip fracture risk in men and women: a meta-analysis of prospective cohort studies and randomized controlled trials. Am J Clin Nutr 2007; 86:1780-1790. (Pubitemid 350232196)
23. Avenell A, Gillespie WJ, Gillespie LD, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and postmenopausal osteoporosis. Cochrane Database Syst Rev 2009:CD000227.
24. Boonen S, Lips P, Bouillon R, et al. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a com parative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 2007; 92:1415-1423. (Pubitemid 46556419)
25. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med 2009; 169:551-561.
26. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010; 341:c3691.
27. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010; 152:315-323.
28. Martyn-St JM, Carroll S. Meta-analysis of walking for preservation of bone mineral density in postmenopausal women. Bone 2008; 43:521-531.
29. Bonaiuti D, Shea B, Iovine R, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2002:CD000333.
30. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:767-773.
31. Orwoll ES, Bauer DC, Vogt TM, Fox KM. Axial bone mass in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1996; 124:187-196. (Pubitemid 26026002)
32. Lau EM, Suriwongpaisal P, Lee JK, et al. Risk factors for hip fracture in Asian men and women: the Asian osteoporosis study. J Bone Miner Res 2001; 16:572-580. (Pubitemid 32173373)
33. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int 2005; 16:155-162. (Pubitemid 40193202)
34. Law MR, Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ 1997; 315:841-846. (Pubitemid 27420442)
35. Vestergaard P, Mosekilde L. Fracture risk associated with smoking: a metaanalysis. J Intern Med 2003; 254:572-583. (Pubitemid 37521854)
36. Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int 2001; 68:259-270. (Pubitemid 32565727)
37. Grainge MJ, Coupland CA, Cliffe SJ, et al. Cigarette smoking, alcohol and caffeine consumption, and bone mineral density in postmenopausal women. The Nottingham EPIC Study Group. Osteoporos Int 1 998; 8:355-363. (Pubitemid 28418270)
38. Dennison E, Eastell R, Fall CH, etal. Determinants of bone loss in elderly men and women: a prospective population-based study. Osteoporos Int 1999; 10:384-391.
39. Felson DT, Zhang Y, Hannan MT, et al. Alcohol intake and bone mineral density in elderly men and women. The Framingham Study. Am J Epidemiol 1995; 142:485-492.
40. Ilich JZ, Brownbill RA, Tamborini L, Crncevic-Orlic Z. To drink or not to drink: how are alcohol, caffeine and past smoking related to bone mineral density in elderly women? J Am Coll Nutr 2002; 21:536-544. (Pubitemid 36026265)
41. Hans D, Durosier C, Kanis JA, et al. Assessment of the 10-year probability of osteoporotic hip fracture combining clinical risk factors and heel bone ultrasound: the EPISEM prospective cohort of 12,958 elderly women. J Bone Miner Res 2008; 23:1045-1051. (Pubitemid 351915726)
42. Porthouse J, Birks YF, Torgerson DJ, et al. Risk factors for fracture in a UK population: a prospective cohort study. QJM 2004; 97:569-574. (Pubitemid 39214323)
43. Dargent-Molina P, Douchin MN, Cormier C, etal. Use of clinical risk factors in elderly women with low bone mineral density to identify women at higher risk of hip fracture: the EPIDOS prospective study. Osteoporos Int 2002; 13:593-599. (Pubitemid 34790633)
44. Ganz DA, Bao Y, Shekelle PG, Rubenstein LZ. Will my patient fall? JAMA 2007; 297:77-86. (Pubitemid 46041729)
45. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med 1988; 319:1701-1707. (Pubitemid 19019577)
46. Gillespie LD, Robertson MC, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2009: CD007146.
47. Kalyani RR, Stein B, Valiyil R, et al. Vitamin D treatment for the prevention of falls in older adults: systematic review and meta-analysis. J Am Geriatr Soc 2010; 58:1299-1310.
48. Cadarette SM, Jaglal SB, Kreiger N, et al. Development and validation of the osteoporosis risk assessment instrument to facilitate selection of women for bone densitometry. CMAJ 2000; 162:1289-1294. (Pubitemid 30304330)
49. Koh LK, Sedrine WB, Torralba TP, et al. A simple tool to identify Asian women at increased risk of osteoporosis. Osteoporos Int 2001; 12:699-705. (Pubitemid 32889171)
50. Michaelsson K, Bergstrom R, Mallmin H, et al. Screening for osteopenia and osteoporosis: selection by body composition. Osteoporos Int 1996; 6:120-126. (Pubitemid 26099833)
51. Lydick E, Cook K, Turpin J, et al. Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Manag Care 1998; 4:37-48. (Pubitemid 28353943)
52. Sedrine WB, Chevallier T, Zegels B, et al. Development and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry. Gynecol Endocrinol 2002; 16:245-250. (Pubitemid 34848386)
53. McLeod KM, Johnson CS. Identifying women with low bone mass: a systematic review of screening tools. Geriatr Nurs 2009; 30:164-173.
54. Weinstein L, Ullery B. Identification of at-risk women for osteoporosis screening. Am J Obstet Gynecol 2000; 183:547-549.
55. Nelson HD, Haney EM, Dana T, et al. Screening for osteoporosis: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2010; 153:99-111.
56. FRAX WHO fracture risk assessment tool. 2009. www.shef.ac.uk/FRAX.
57. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19:385-397.
58. Dawson-Hughes B, Tosteson AN, Melton LJ III, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008; 19:449-458.
59. Schuit SC, van der Klift M, Weel AE, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004; 34:195-202. (Pubitemid 38142449)
60. Bagger YZ, Tanko LB, Alexandersen P, et al. The long-term predictive value of bone mineral density measurements for fracture risk is independent of the site of measurement and the age at diagnosis: results from the Prospective Epidemiological Risk Factors study. Osteoporos Int 2006; 17:471-477.
61. Fink HA, Harrison SL, Taylor BC, et al. Differences in site-specific fracture risk among older women with discordant results for osteoporosis at hip and spine: study of osteoporotic fractures. J Clin Densitom 2008; 11:250-259.
62. National Osteoporosis Foundation. Clinician's guide to the prevention and treatment of osteoporosis [generic]. Washington, District of Columbia: National Osteoporosis Foundation; 2008.
63. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290:1729-1738. (Pubitemid 37430623)
64. Cauley JA, Black DM, Barrett-Connor E, et al. Effects of hormone replacement therapy on clinical fractures and height loss: the Heart and Estrogen/ Progestin Replacement Study (HERS). Am J Med 2001; 110:442-450.
65. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605-613. (Pubitemid 28502636)
66. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289:3243-3253. (Pubitemid 37430077)
67. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349:523-534. (Pubitemid 36951364)
68. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280:2077-2082. (Pubitemid 29014065)
69. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87:3609-3617. (Pubitemid 34879503)
70. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282:637-645. (Pubitemid 29384151)
71. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007; 146:326-339. (Pubitemid 351650593)
72. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333:1437-1443.
73. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344:333-340. (Pubitemid 32107641)
74. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999; 9:461-468. (Pubitemid 29231740)
75. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346:653-661. (Pubitemid 34815869)
76. Chesnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19:1241-1249.
77. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356:1809-1822. (Pubitemid 46698462)
78. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434-1441. (Pubitemid 32402100)
79. Cummings SR, San MJ, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756-765.
80. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bispho-sphonates: a critical review. Am J Med 2009; 122 (2 Suppl):S33-S45.
81. Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA 2010; 304:1480-1484.
82. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bispho-sphonates and risk of esophageal cancer. JAMA 2010; 304:657-663.
83. Watts NB, Diab DL Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010; 95:1555-1565.
84. Van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000; 39:1383-1389. (Pubitemid 32045866)
85. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of gluco-corticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62:1515-1526.